Iscartrelvir

Iscartrelvir
Clinical data
Other namesWPV01; WU-04
Identifiers
  • N-[(1S,2R)-2-[4-bromo-2-(methylcarbamoyl)-6-nitroanilino]cyclohexyl]isoquinoline-4-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
PDB ligand
Chemical and physical data
FormulaC24H24BrN5O4
Molar mass526.391 g·mol−1
3D model (JSmol)
  • CNC(=O)C1=C(C(=CC(=C1)Br)[N+](=O)[O-])N[C@@H]2CCCC[C@@H]2NC(=O)C3=CN=CC4=CC=CC=C43
  • InChI=InChI=1S/C24H24BrN5O4/c1-26-23(31)17-10-15(25)11-21(30(33)34)22(17)28-19-8-4-5-9-20(19)29-24(32)18-13-27-12-14-6-2-3-7-16(14)18/h2-3,6-7,10-13,19-20,28H,4-5,8-9H2,1H3,(H,26,31)(H,29,32)/t19-,20+/m1/s1
  • Key:BPLNOSFMIIASSJ-UXHICEINSA-N

Iscartrelvir is an investigational new drug developed by the Westlake University for the treatment of COVID-19. It targets the SARS-CoV-2 3CL protease, which is crucial for the replication of the virus responsible for COVID-19.[1][2]

See also

References

  1. ^ Yang L, Wang Z (September 2023). "Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China". European Journal of Medicinal Chemistry. 257: 115503. doi:10.1016/j.ejmech.2023.115503. PMC 10193775. PMID 37229831.
  2. ^ Hou N, Shuai L, Zhang L, Xie X, Tang K, Zhu Y, et al. (February 2023). "Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro". ACS Central Science. 9 (2): 217–227. doi:10.1021/acscentsci.2c01359. PMC 9885526. PMID 36844503.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.